Share additional data from ruxolitinib twice-daily combination studies with zilurgisertib and INCB57643
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 31 Oct 2023
- Due
- 31 Dec 2023
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Additional data from these studies are anticipated to be shared in the fourth quarter of 2023.”
What we found
Evidence strength A What the grades mean
A later 10-K says updated data on the ruxolitinib combination trials were presented at the December 2023 ASH meeting, within the Q4 2023 window.
-
A Incyte 10-K filed 2024-02-13
“were presented in June 2023 at the American Society of Clinical Oncology (ASCO) annual meeting and in December 2023 at the American Society of Hematology (ASH) meeting.” ✓ confirmed on the page
-
A Incyte 10-Q filed 2024-04-30
“updated data demonstrating early signals of clinical activity of both agents in monotherapy and in combination with ruxolitinib were presented in June 2023” ✓ confirmed on the page
Market reaction: the shares moved +1.8% against the S&P 500 over the three sessions around the disclosure (12 Feb 2024 to 15 Feb 2024). What this measures
Checked 10 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Share
- Deliverable
- Additional data from ruxolitinib BID combination studies
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- Medium
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Incyte? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2023-INCY-005715 · Corrections policy